The proposed trial shall address whether Naproxen, a nonsteroidal anti-inflammatory agent in widespread clinical use primarily for the treatment of pain and inflammation, can safely and effectively be given in a once daily dose to subjects at risk for a mismatch repair deficient colon carcinoma, and how and whether it modulates a series of biomarkers and other parameters in this specific population. The trial shall be performed at the MD Anderson Cancer Center, the Dana Farber Cancer Center and the University of Michigan. All three institutions shall participate in the various aspects of the trial.

Agency
National Institute of Health (NIH)
Type
Station Support Contracts (N03)
Project #
261201200034I-0-26100003-1
Application #
8762954
Study Section
Project Start
2013-09-20
Project End
2017-09-19
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$1,050,763
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030